IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.690
AS - Asia 4.657
EU - Europa 4.501
SA - Sud America 1.003
AF - Africa 147
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 10
Totale 17.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.516
SG - Singapore 2.095
CN - Cina 1.212
DE - Germania 1.204
BR - Brasile 778
SE - Svezia 745
IT - Italia 466
UA - Ucraina 432
FR - Francia 422
VN - Vietnam 380
GB - Regno Unito 235
IE - Irlanda 231
PL - Polonia 210
IN - India 185
FI - Finlandia 154
ID - Indonesia 149
JP - Giappone 127
RU - Federazione Russa 127
HK - Hong Kong 92
TR - Turchia 82
CA - Canada 77
BD - Bangladesh 70
AR - Argentina 62
IQ - Iraq 54
MX - Messico 54
EC - Ecuador 48
NL - Olanda 48
BE - Belgio 46
ES - Italia 43
CI - Costa d'Avorio 35
CL - Cile 33
PK - Pakistan 32
ZA - Sudafrica 30
AT - Austria 28
VE - Venezuela 26
RO - Romania 22
KE - Kenya 21
IL - Israele 20
UZ - Uzbekistan 20
AU - Australia 19
CO - Colombia 19
PE - Perù 17
SA - Arabia Saudita 17
KR - Corea 13
JO - Giordania 12
LT - Lituania 12
OM - Oman 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
EG - Egitto 11
MA - Marocco 11
TN - Tunisia 11
AZ - Azerbaigian 10
BG - Bulgaria 10
PY - Paraguay 10
IR - Iran 9
DZ - Algeria 8
CZ - Repubblica Ceca 7
GR - Grecia 7
MY - Malesia 7
BZ - Belize 6
CR - Costa Rica 6
PH - Filippine 6
PT - Portogallo 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
PR - Porto Rico 5
UY - Uruguay 5
AO - Angola 4
BO - Bolivia 4
DK - Danimarca 4
EU - Europa 4
HN - Honduras 4
HU - Ungheria 4
JM - Giamaica 4
LK - Sri Lanka 4
LU - Lussemburgo 4
NI - Nicaragua 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
CY - Cipro 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TJ - Tagikistan 2
Totale 17.005
Salva come PNG Salva come JPEG
Città #
Singapore 1.111
Chandler 891
Ashburn 786
San Jose 480
Jacksonville 285
Beijing 250
San Mateo 230
Dublin 221
New York 197
Warsaw 174
Wilmington 156
Ann Arbor 154
Nanjing 141
Jakarta 135
Houston 132
Los Angeles 129
Ho Chi Minh City 126
Lauterbourg 125
Dearborn 116
Woodbridge 114
Boston 104
Tokyo 99
Cattolica 96
Hanoi 96
Hong Kong 89
Chicago 86
Dallas 81
Frankfurt am Main 81
Hefei 80
Princeton 71
Milan 69
Redwood City 69
São Paulo 68
Moscow 66
Lawrence 61
Cambridge 58
North Bergen 57
Nürnberg 53
Seattle 53
Marseille 50
Munich 50
Rome 50
Fairfield 49
Buffalo 47
Bremen 46
Izmir 46
Nanchang 45
Santa Clara 45
Fuzhou 42
Hangzhou 40
London 40
Brussels 38
Shanghai 38
Redmond 37
Abidjan 35
Nuremberg 34
Tianjin 31
Mountain View 30
Helsinki 28
Shenyang 27
Zhengzhou 26
Council Bluffs 25
Norwalk 25
Boardman 24
Hebei 24
Orem 24
Changsha 23
Chennai 23
Düsseldorf 23
Paris 23
Turku 23
Amsterdam 22
Brooklyn 22
Denver 20
Montreal 20
Porto Alegre 20
Rio de Janeiro 20
Des Moines 19
Kunming 19
Mexico City 19
Nairobi 19
Tashkent 19
Belo Horizonte 18
Stockholm 18
Atlanta 17
Baghdad 17
Haiphong 17
Kent 17
Fortaleza 16
Leawood 16
Poplar 16
San Francisco 16
Brasília 15
Guayaquil 15
Jiaxing 15
Johannesburg 15
Millbury 15
Pune 15
The Dalles 15
Da Nang 14
Totale 9.007
Salva come PNG Salva come JPEG
Nome #
International consensus guidance for management of myasthenia gravis: Executive summary 249
Single-centre 40-year results of redo operation for recurrent thymomas. 247
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 236
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 235
Myasthenia gravis 235
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 209
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 206
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 203
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 201
Thymoma in patients with MG: characteristics and long-term outcome 195
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 195
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 188
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 186
SFEMG: A piece in the diagnostic puzzle of myasthenia 181
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 180
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 179
When myasthenia gravis is not all. 179
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 177
A Genome-wide Association Study of Myasthenia Gravis 176
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 176
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 172
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 172
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 169
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 168
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 166
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 164
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 161
Myasthenia gravis with antibodies to MuSK: an update 159
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 157
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 154
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 153
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 153
Response to therapy in myasthenia gravis with anti-MuSK antibody 151
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 149
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 147
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 147
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 146
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 142
BAFF serum levels in myasthenia gravis: effects of therapy 141
Anti-AChR-negative myasthenia gravis: clinical and immunological features 141
Multiple paraneoplastic diseases associated with thymoma. 140
Determinants of cognitive impairment in elderly myasthenia gravis patients 139
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 138
Prognostic grading after complete resection for thymic malignancies 138
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 138
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 138
Diagnostic features and subtyping of thymoma lymph node metastases 137
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 137
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 136
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 134
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 132
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 130
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 129
Clinical heterogeneity of seronegative myasthenia gravis 128
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 128
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 127
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 126
Immunosuppressive therapies in myasthenia gravis 125
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 124
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 124
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 123
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 121
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 120
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 120
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 117
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 116
Spontaneous recovery from anti-NMDAR encephalitis 114
Acquired myasthenia gravis in childhood. 114
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 114
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 112
In sickness and in health: when myasthenia gravis is a conjugal matter 112
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 111
Imatinib mesylate in thymic epithelial malignancies. 110
Thymectomy in the treatment of myasthenia gravis: report of 247 patients 109
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology 108
Thymoma recurrences in myasthenia gravis patients 108
Course and treatment of myasthenia gravis during pregnancy 107
Early-onset myasthenia gravis: clinical characteristics and response to therapy 107
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 107
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 106
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 106
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 105
Anti-MuSK antibodies: Correlation with myasthenia gravis severity 104
Benefit and danger from immunotherapy in myasthenia gravis 104
Controversies in Ocular Myasthenia Gravis 103
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 103
Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report 103
Concordance between radioimmunoassay and fixed cell-based assay in subjects without myasthenia gravis: optimizing the diagnostic approach 103
A practical guide to the recognition and management of myasthenia gravis 101
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 100
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 99
Antibody-phenotype correlation in stiff-person syndrome 98
Minimal manifestation status and prednisone withdrawal in the MGTX trial 98
Myasthenia gravis during interferon alfa therapy 97
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 96
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 96
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 95
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 95
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension 94
Risk of cancer in patients with myasthenia gravis 94
Totale 14.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.704
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021229 0 0 0 0 0 0 0 0 0 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20252.252 54 90 181 60 171 66 72 119 376 172 455 436
2025/20265.776 954 176 358 805 1.149 302 970 288 432 342 0 0
Totale 17.253